Cargando…

Antibody profile in post-vaccinated & SARS-CoV-2 infected individuals

BACKGROUND & OBJECTIVES: During the COVID-19 pandemic it was important to assess the antibody profile in individuals vaccinated with Covaxin (BBV152) and Covishield (ChAdOx1 nCoV-19) with both 28 and 84 days gaps between two doses, those infected with SARS-CoV-2 and post-COVID-19-infected indivi...

Descripción completa

Detalles Bibliográficos
Autores principales: Patil, Rucha, Shanbhag, Sharda, Shankarkumar, Aruna, Madkaikar, Manisha
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9807196/
https://www.ncbi.nlm.nih.gov/pubmed/36124500
http://dx.doi.org/10.4103/ijmr.ijmr_3330_21
_version_ 1784862669222707200
author Patil, Rucha
Shanbhag, Sharda
Shankarkumar, Aruna
Madkaikar, Manisha
author_facet Patil, Rucha
Shanbhag, Sharda
Shankarkumar, Aruna
Madkaikar, Manisha
author_sort Patil, Rucha
collection PubMed
description BACKGROUND & OBJECTIVES: During the COVID-19 pandemic it was important to assess the antibody profile in individuals vaccinated with Covaxin (BBV152) and Covishield (ChAdOx1 nCoV-19) with both 28 and 84 days gaps between two doses, those infected with SARS-CoV-2 and post-COVID-19-infected individuals vaccinated with only one dose of either of the vaccines. The present study was aimed to assess these objectives. METHODS: Fifty real time reverse transcription–polymerase chain reaction (qRT-PCR)-confirmed COVID-19-infected individuals, along with 90 COVID-19-naïve (BBV152 and ChAdOx1 nCov-19)–vaccinated individuals, were included in the study. Individuals who received a single dose of either vaccine with a confirmed past diagnosis of SARS-CoV-2 infection (n=15) were also included. Blood samples were collected strictly between the 4(th) and 5(th) wk after development of symptoms for SARS-CoV-2 infected individuals and after the first/second vaccination dose. Antibody profile assessment was done using whole-virus, spike-receptor binding domain (RBD) and nucleocapsid-specific ELISA kits along with neutralizing antibody kit. RESULTS: There was an overall 97.7 per cent seropositivity rate in vaccinated individuals, and a strong correlation (R(2)=0.8, P<0.001) between neutralizing and spike-RBD antibodies. Among individuals who received two standard doses of ChAdOx1 nCoV-19 vaccine, the spike antibody levels developed were of higher titre with a longer prime boost interval than in those with shorter intervals (P<0.01). Individuals vaccinated with two doses as well as only one dose post-SARS-CoV-2 infection had high neutralizing and spike-specific antibodies. INTERPRETATION & CONCLUSIONS: High neutralizing and spike-specific antibodies were developed in individuals vaccinated only with one dose of either vaccine post-SARS-CoV-2 infection. With the main priority being vaccinating majority of the population in our country, single-dose administration to such individuals would be a sensible way to make the most of the limited supplies. Furthermore, neutralizing antibody levels observed in COVID-19-naïve vaccinees imply the need for booster vaccination.
format Online
Article
Text
id pubmed-9807196
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Wolters Kluwer - Medknow
record_format MEDLINE/PubMed
spelling pubmed-98071962023-01-03 Antibody profile in post-vaccinated & SARS-CoV-2 infected individuals Patil, Rucha Shanbhag, Sharda Shankarkumar, Aruna Madkaikar, Manisha Indian J Med Res Original Article BACKGROUND & OBJECTIVES: During the COVID-19 pandemic it was important to assess the antibody profile in individuals vaccinated with Covaxin (BBV152) and Covishield (ChAdOx1 nCoV-19) with both 28 and 84 days gaps between two doses, those infected with SARS-CoV-2 and post-COVID-19-infected individuals vaccinated with only one dose of either of the vaccines. The present study was aimed to assess these objectives. METHODS: Fifty real time reverse transcription–polymerase chain reaction (qRT-PCR)-confirmed COVID-19-infected individuals, along with 90 COVID-19-naïve (BBV152 and ChAdOx1 nCov-19)–vaccinated individuals, were included in the study. Individuals who received a single dose of either vaccine with a confirmed past diagnosis of SARS-CoV-2 infection (n=15) were also included. Blood samples were collected strictly between the 4(th) and 5(th) wk after development of symptoms for SARS-CoV-2 infected individuals and after the first/second vaccination dose. Antibody profile assessment was done using whole-virus, spike-receptor binding domain (RBD) and nucleocapsid-specific ELISA kits along with neutralizing antibody kit. RESULTS: There was an overall 97.7 per cent seropositivity rate in vaccinated individuals, and a strong correlation (R(2)=0.8, P<0.001) between neutralizing and spike-RBD antibodies. Among individuals who received two standard doses of ChAdOx1 nCoV-19 vaccine, the spike antibody levels developed were of higher titre with a longer prime boost interval than in those with shorter intervals (P<0.01). Individuals vaccinated with two doses as well as only one dose post-SARS-CoV-2 infection had high neutralizing and spike-specific antibodies. INTERPRETATION & CONCLUSIONS: High neutralizing and spike-specific antibodies were developed in individuals vaccinated only with one dose of either vaccine post-SARS-CoV-2 infection. With the main priority being vaccinating majority of the population in our country, single-dose administration to such individuals would be a sensible way to make the most of the limited supplies. Furthermore, neutralizing antibody levels observed in COVID-19-naïve vaccinees imply the need for booster vaccination. Wolters Kluwer - Medknow 2022 2022-10-28 /pmc/articles/PMC9807196/ /pubmed/36124500 http://dx.doi.org/10.4103/ijmr.ijmr_3330_21 Text en Copyright: © 2022 Indian Journal of Medical Research https://creativecommons.org/licenses/by-nc-sa/4.0/This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
spellingShingle Original Article
Patil, Rucha
Shanbhag, Sharda
Shankarkumar, Aruna
Madkaikar, Manisha
Antibody profile in post-vaccinated & SARS-CoV-2 infected individuals
title Antibody profile in post-vaccinated & SARS-CoV-2 infected individuals
title_full Antibody profile in post-vaccinated & SARS-CoV-2 infected individuals
title_fullStr Antibody profile in post-vaccinated & SARS-CoV-2 infected individuals
title_full_unstemmed Antibody profile in post-vaccinated & SARS-CoV-2 infected individuals
title_short Antibody profile in post-vaccinated & SARS-CoV-2 infected individuals
title_sort antibody profile in post-vaccinated & sars-cov-2 infected individuals
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9807196/
https://www.ncbi.nlm.nih.gov/pubmed/36124500
http://dx.doi.org/10.4103/ijmr.ijmr_3330_21
work_keys_str_mv AT patilrucha antibodyprofileinpostvaccinatedsarscov2infectedindividuals
AT shanbhagsharda antibodyprofileinpostvaccinatedsarscov2infectedindividuals
AT shankarkumararuna antibodyprofileinpostvaccinatedsarscov2infectedindividuals
AT madkaikarmanisha antibodyprofileinpostvaccinatedsarscov2infectedindividuals